Minapharm PharmaceuticalsCAI:MIPH -0.27%41 Piotroski F-Score is 7 as of Jul. 13, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.13 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 979 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 91.93% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Minapharm Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Minapharm Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
CAI:MIPH'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 7
Current: 7
During the past 5 years, the highest Piotroski F-Score of Minapharm Pharmaceuticals was 7. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Minapharm Pharmaceuticals Piotroski F-Score Related Terms
Minapharm Pharmaceuticals Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Dec25) TTM:
Last Year (Dec24) TTM:
Net Income was -1.956 + 39.961 + 16.846 + -14.636 = E£40 Mil. Cash Flow from Operations was -76.519 + 378.642 + -68.128 + 230.81 = E£465 Mil. Revenue was 1607.149 + 1731.8 + 1501.116 + 1598.112 = E£6,438 Mil. Gross Profit was 578.487 + 698.538 + 484.501 + 544.279 = E£2,306 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(12003.296 + 12306.829 + 12448.835 + 13379.113 + 13148.14) / 5 = E£12657.2426 Mil. Total Assets at the begining of this year (Dec24) was E£12,003 Mil. Long-Term Debt & Capital Lease Obligation was E£1,763 Mil. Total Current Assets was E£6,253 Mil. Total Current Liabilities was E£4,807 Mil.
Net Income was -39.344 + -26.874 + 137.237 + 86.047 = E£157 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Minapharm Pharmaceuticals's current Net Income (TTM) was 40.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Minapharm Pharmaceuticals's current Cash Flow from Operations (TTM) was 465.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Minapharm Pharmaceuticals's return on assets of this year was 0.00335033. Minapharm Pharmaceuticals's return on assets of last year was 0.01804617.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Minapharm Pharmaceuticals's gearing of this year was 0.13928776. Minapharm Pharmaceuticals's gearing of last year was 0.25681588.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Minapharm Pharmaceuticals's current ratio of this year was 1.30074013. Minapharm Pharmaceuticals's current ratio of last year was 1.24640369.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Minapharm Pharmaceuticals's number of shares in issue this year was 12.293. Minapharm Pharmaceuticals's number of shares in issue last year was 12.293.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Minapharm Pharmaceuticals's gross margin of this year was 0.35814564. Minapharm Pharmaceuticals's gross margin of last year was 0.34584783.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Minapharm Pharmaceuticals's asset turnover of this year was 0.53636743. Minapharm Pharmaceuticals's asset turnover of last year was 0.64337602.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
1
+
1
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Minapharm Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Minapharm Pharmaceuticals (CAI:MIPH) has a Piotroski F-Score of 7 as of Jul. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Minapharm Pharmaceuticals and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Minapharm Pharmaceuticals' Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #79 out of 979 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Minapharm Pharmaceuticals' Piotroski F-Score too high?
Minapharm Pharmaceuticals' current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Minapharm Pharmaceuticals' value of 7 is 40% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #79 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #79 out of 979 companies for Piotroski F-Score. This places Minapharm Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Minapharm Pharmaceuticals' value of 7 is 40% above this benchmark. Historically, Minapharm Pharmaceuticals' own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.13, compared to a current price of E£698.08 — trading 92.8% above its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Drug Manufacturers industry median of 5.00. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Piotroski F-Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.8% above its estimated GF Value™ of E£362.13.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: E£362.13 vs. price of E£698.08 (92.8% above fair value)
Industry Position: 40% above the Drug Manufacturers median (#79 of 979)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
